Data · dataset · 2024
A therapeutic small molecule enhances γ-oscillations and improves cognition/memory in Alzheimer’s disease model mice
Listed in DataCite
Brain rhythms provide the timing for the recruitment of brain activity required for linking together neuronal ensembles engaged in specific tasks.
Description
The γ-oscillations (30-120 Hz) orchestrate neuronal circuits underlying cognitive processes and working memory. These oscillations are reduced in numerous neurological and psychiatric disorders, including early cognitive decline in Alzheimer’s disease (AD).
Here we report on a potent brain-permeable small molecule, DDL-920 that increases γ-oscillations and improves cognition/memory in a mouse model of AD, thus showing promise as a new class of therapeutics for AD. We employed anatomical, in vitro, and in vivo electrophysiological, and behavioral methods to examine the effects of our lead therapeutic candidate small molecule. As a first in CNS pharmacotherapy, our lead molecule acts as a potent, efficacious, and selective negative allosteric modulator (NAM) of the γ-aminobutyric acid type A receptors (GABAARs) most likely assembled from α1β2δ subunits.
Read the rest (1 more)
These receptors, identified through anatomical and pharmacological means, underlie the tonic inhibition of parvalbumin (PV) expressing interneurons (PV+INs) critically involved in the generation of γ-oscillations. When orally administered twice daily for two weeks, DDL-920 restored the cognitive/memory impairments of 3-4-month-old AD model mice as measured by their performance in the Barnes maze. Our approach is unique as it is meant to enhance cognitive performance and working memory in a state-dependent manner by engaging and amplifying the brain’s endogenous γ-oscillations through enhancing the function of PV+INs.
Links
Where it is published
- Repository landing page datadryad.org/dataset/doi:10.5061/dryad.4j0zpc8mw ↗
landing page · from DataCite
- DOI doi.org/10.5061/dryad.4j0zpc8mw ↗
DOI / persistent id · from DataCite
Documentation and papers
- Creative Commons Zero v1.0 Universal creativecommons.org/publicdomain/zero/1.0/legalcode ↗
license · from DataCite
- IsCitedBy 10.1101/2023.12.04.569994 doi.org/10.1101/2023.12.04.569994 ↗
publication · from DataCite
- IsCitedBy 10.1073/pnas.2400420121 doi.org/10.1073/pnas.2400420121 ↗
publication · from DataCite
Catalogue records · 2
- DataCite API api.datacite.org/dois/10.5061/dryad.4j0zpc8mw ↗
metadata API · from DataCite
- DataCite Commons commons.datacite.org/doi.org/10.5061/dryad.4j0zpc8mw ↗
catalogue entry · from DataCite
Topics
- Stated by source
- Basic medicine
- Inferred from text
- Disease 75% · Neurosciences 70%
Provenance · 1 source records, 11 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| DataCite | 10.5061/dryad.4j0zpc8mw | 14 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · DataCite | connector:datacite@1.0.0 | /data/attributes/rightsList |
| byte_size | source · DataCite | connector:datacite@1.0.0 | |
| concepts[disease].local:disease:disease | enrichment · DataCite | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].anzsrc:group:3209 | enrichment · DataCite | taxonomy-embedding@1.1.0 | title+keywords+description (70%) |
| concepts[field].fos:basic-medicine | source · DataCite | connector:datacite@1.0.0 | |
| created_date | source · DataCite | connector:datacite@1.0.0 | |
| description | source · DataCite | connector:datacite@1.0.0 | /data/attributes/descriptions |
| license | source · DataCite | connector:datacite@1.0.0 | /data/attributes/rightsList |
| publication_date | source · DataCite | connector:datacite@1.0.0 | /data/attributes/dates |
| title | source · DataCite | connector:datacite@1.0.0 | /data/attributes/titles/0/title |
| version_label | source · DataCite | connector:datacite@1.0.0 |